While nearly 90% of myasthenia gravis patients have autoantibodies targeting AChR and/or the muscle-specific tyrosine kinase (MuSK), other autoantibodies targeting striated muscles, particularly the sarcomere protein Titin, have been detected in some myasthenia gravis patients. This evidence concerns the gene TTN and myasthenia gravis.